tiprankstipranks
Trending News
More News >

MIRA Pharmaceuticals Completes Key Neurotoxicity Study for Ketamir-2

Story Highlights
  • MIRA Pharmaceuticals completed an FDA-required study showing no brain toxicity for Ketamir-2.
  • The study confirmed Ketamir-2’s safety, unlike MK-801, supporting MIRA’s regulatory progress.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
MIRA Pharmaceuticals Completes Key Neurotoxicity Study for Ketamir-2

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from MIRA Pharmaceuticals, Inc. ( (MIRA) ).

On May 6, 2025, MIRA Pharmaceuticals announced the successful completion of an FDA-required neurotoxicity study for its drug Ketamir-2, which showed no signs of brain toxicity. The study, conducted on Sprague-Dawley rats, demonstrated that Ketamir-2 did not cause neuropathologic changes, unlike the positive control MK-801, which showed evidence of neurotoxic lesions. These findings will be submitted to the FDA, potentially impacting MIRA’s regulatory progress and industry positioning by confirming the safety profile of Ketamir-2.

More about MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development of novel oral NMDA receptor antagonists. The company is listed on NASDAQ under the ticker MIRA and is engaged in clinical development programs aimed at addressing neurotoxicity concerns associated with similar compounds.

Average Trading Volume: 1,185,430

Technical Sentiment Signal: Hold

See more data about MIRA stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1